ATE212842T1 - Quinoxalin-derivate zur behandlung von tinnitus - Google Patents

Quinoxalin-derivate zur behandlung von tinnitus

Info

Publication number
ATE212842T1
ATE212842T1 AT96306764T AT96306764T ATE212842T1 AT E212842 T1 ATE212842 T1 AT E212842T1 AT 96306764 T AT96306764 T AT 96306764T AT 96306764 T AT96306764 T AT 96306764T AT E212842 T1 ATE212842 T1 AT E212842T1
Authority
AT
Austria
Prior art keywords
tinnitus
treatment
quinoxaline derivatives
medicament
chem
Prior art date
Application number
AT96306764T
Other languages
English (en)
Inventor
Steven Bradley Sands
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of ATE212842T1 publication Critical patent/ATE212842T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT96306764T 1995-10-10 1996-09-18 Quinoxalin-derivate zur behandlung von tinnitus ATE212842T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US521795P 1995-10-10 1995-10-10

Publications (1)

Publication Number Publication Date
ATE212842T1 true ATE212842T1 (de) 2002-02-15

Family

ID=21714768

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96306764T ATE212842T1 (de) 1995-10-10 1996-09-18 Quinoxalin-derivate zur behandlung von tinnitus

Country Status (10)

Country Link
US (1) US5840723A (de)
EP (1) EP0784973B1 (de)
JP (1) JPH09132530A (de)
AT (1) ATE212842T1 (de)
CA (1) CA2187402C (de)
DE (1) DE69619088T2 (de)
DK (1) DK0784973T3 (de)
ES (1) ES2168119T3 (de)
MX (1) MX9604692A (de)
PT (1) PT784973E (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9821179D0 (en) * 1998-09-30 1998-11-25 Merck Sharp & Dohme Therapeutic use
FR2787028B1 (fr) * 1998-12-15 2002-10-18 Aventis Pharma Sa Utilisation du riluzole dans le traitement des traumatismes acoustiques
US6362227B1 (en) * 1999-03-02 2002-03-26 Sepracor, Inc. Methods for the treatment of tinnitus and other disorders using R(−)ketoptofen
US6436449B2 (en) 2000-03-02 2002-08-20 Bo Gidlund Use of a composition

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2123546T3 (es) * 1991-11-15 1999-01-16 Phafag Ag Uso de derivados de 1-(aminoalquil)-3-quinoxalina-2-ona para la preparacion de composiciones neuroprotectoras.
EP0542689B1 (de) * 1991-11-15 1998-09-23 Phafag Aktiengesellschaft Verwendung von 1-(aminoalkyl)-3-Quinoxalin-2-on Derivaten zur Herstellung von neuroprotektiven Mitteln
GB9419318D0 (en) * 1994-09-24 1994-11-09 Pfizer Ltd Therapeutic agents

Also Published As

Publication number Publication date
PT784973E (pt) 2002-06-28
CA2187402A1 (en) 1997-04-11
DE69619088T2 (de) 2002-07-11
US5840723A (en) 1998-11-24
DK0784973T3 (da) 2002-03-18
CA2187402C (en) 2000-08-08
DE69619088D1 (de) 2002-03-21
ES2168119T3 (es) 2002-06-01
EP0784973B1 (de) 2002-02-06
MX9604692A (es) 1998-04-30
JPH09132530A (ja) 1997-05-20
EP0784973A2 (de) 1997-07-23
EP0784973A3 (de) 1999-12-15

Similar Documents

Publication Publication Date Title
MY117896A (en) Quinazoline derivatives
SE9604786D0 (sv) New compounds
NO912410L (no) Fremgangsmaate for fremstilling av terapeutisk aktive heterocyklen-derivater.
DE69623899D1 (de) Behandlung von Tinnitus mit neuroprotektiven Wirkstoffen
DE69331171D1 (de) Chinolin und Chinazolin Derivate zur Behandlung von Arthritis
ATE79257T1 (de) Verwendung von tetrahydrobenz(c,d>indol-6carboxamiden zur herstellung von arzneimitteln zur behandlung von angstzustaenden.
DE3888340D1 (de) Verwendung von 1,4-disubstituierten-Piperidinyl-Verbindungen zur Herstellung eines Arzneimittels zur Behandlung von Schlaflosigkeit.
DE69828197D1 (de) Amidderivate zur behandlung neurodegenerativer erkrankungen der netzhaut
DE69307674D1 (de) HIV-Proteaseinhibitoren und ihre Verwendung zur Behandlung von AIDS
DE69419954D1 (de) Arzneimittel zur Behandlung von Hauterkrankungen
ATE212842T1 (de) Quinoxalin-derivate zur behandlung von tinnitus
SE9702716D0 (sv) Substituted phenylazacycloalkanes in the treatment of cognitive disorders
ATE250027T1 (de) Azetidincarboxamidderivate zur behandlung von zns-erkrankungen
DE69827706D1 (de) 5-(Heteroaryl)alkyl)-3-oxo-pyrido(1,2-a)benzimidazol-4-carboxamid (PBI) Derivate zur Behandlung von Störungen des zentralen Nervensystems
ATE186912T1 (de) Carbamoylpyrrolidon-derivate zur behandlung von depressionen und cerebrovasculären störungen
ATE124259T1 (de) Thiazolidine-2,4-dione für die behandlung der hypertonie.
DE60005525D1 (de) 2-aminotetraline zur behandlung von glaukom
ATE136217T1 (de) Verwendung von imino-derivaten von etianaldehyd zur herstellung eines arzneimittels zur behandlung des bluthochdrucks
DE3782229D1 (de) Verwendung von 2-oxo-imidazolidin-derivaten zur behandlung von nierenkrankheiten.
DE69902142D1 (de) Azetidincarboxamidderivate zur behandlung von zns-erkrankungen
ATE81466T1 (de) Verwendung von 2-oxo-imidazolidin-derivaten zur prophylaxe und zur behandlung von herzinsuffizienz.
DE3884878D1 (de) Uricosuretische Zusammensetzung.
DE69722630D1 (de) Therapeutisches mittel zur behandlung von nierenerkrankungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee